Free Trial
→ Trump Quietly Planning $15 Trillion Crypto Shocker (From Paradigm Press) (Ad) Buy MLTX Stock  Free MLTX Stock Alerts

MoonLake Immunotherapeutics (MLTX) Financials

MoonLake Immunotherapeutics logo
$38.58 -0.35 (-0.90%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$38.58 0.00 (0.00%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for MoonLake Immunotherapeutics

Annual Income Statements for MoonLake Immunotherapeutics

This table shows MoonLake Immunotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Income / (Loss) Attributable to Common Shareholders		 -119 -36 -50 -4.54
Consolidated Net Income / (Loss)		 -121 -44 -65 -4.54
Net Income / (Loss) Continuing Operations		 -121 -44 -65 -4.54
Total Pre-Tax Income 		-121 -44 -64 -4.54
Total Operating Income		 -143 -54 -65 -4.57
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 143 54 65 4.57
Selling, General & Admin Expense		 30 22 23 4.57
Research & Development Expense		 113 32 42 -
Total Other Income / (Expense), net		 22 10 0.59 0.03
Other Income / (Expense), net		 22 10 0.59 -
Income Tax Expense		 0.28 0.09 0.04 -
Net Income / (Loss) Attributable to Noncontrolling Interest		 -2.31 -8.07 -15 -
Basic Earnings per Share		 ($1.89) ($0.73) ($1.70) ($0.31)
Weighted Average Basic Shares Outstanding		 62.87M 49.12M 29.36M 14.81M
Diluted Earnings per Share		 ($1.89) ($0.73) ($1.70) ($0.31)
Weighted Average Diluted Shares Outstanding		 62.87M 49.12M 29.36M 14.81M
Weighted Average Basic & Diluted Shares Outstanding		 64.01M 63.89M 52.70M 11.93M

Quarterly Income Statements for MoonLake Immunotherapeutics

This table shows MoonLake Immunotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -46 -35 -24 -14 -7.44 -9.43 -10 -9.00 -12 -10
Consolidated Net Income / (Loss)		 -46 -36 -25 -14 -7.89 -12 -12 -12 -16 -15
Net Income / (Loss) Continuing Operations		 -46 -36 -25 -14 -7.89 -12 -12 -12 -16 -15
Total Pre-Tax Income 		-46 -36 -25 -14 -7.84 -12 -12 -12 -16 -15
Total Operating Income		 -50 -43 -31 -20 -15 -13 -13 -13 -17 -15
Total Operating Expenses		 50 43 31 20 15 13 13 13 17 15
Selling, General & Admin Expense		 9.22 7.38 6.92 6.81 6.93 5.39 4.48 5.52 5.53 5.75
Research & Development Expense		 40 36 24 13 8.10 7.59 8.70 7.42 11 9.02
Total Other Income / (Expense), net		 3.23 7.09 5.90 5.92 7.19 1.39 0.84 0.72 0.24 0.04
Other Income / (Expense), net		 3.23 7.09 5.90 5.92 7.19 1.39 0.84 0.72 0.24 0.04
Income Tax Expense		 0.04 0.09 0.08 0.07 0.04 0.03 0.01 0.01 0.01 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.79 -0.72 -0.49 -0.30 -0.45 -2.19 -2.21 -3.21 -4.61 -4.63
Basic Earnings per Share		 ($0.50) ($0.56) ($0.39) ($0.44) $0.37 ($0.18) ($0.46) ($0.46) $2.08 ($0.27)
Weighted Average Basic Shares Outstanding		 62.87M 62.90M 62.87M 125.27M 49.12M 53.52M 87.44M 78.12M 29.36M 36.93M
Diluted Earnings per Share		 ($0.50) ($0.56) ($0.39) ($0.44) $0.37 ($0.18) ($0.46) ($0.46) $2.08 ($0.27)
Weighted Average Diluted Shares Outstanding		 62.87M 62.90M 62.87M 125.27M 49.12M 53.52M 87.44M 78.12M 29.36M 36.93M
Weighted Average Basic & Diluted Shares Outstanding		 64.01M 63.91M 63.88M 63.87M 63.89M 62.45M 62.45M 52.70M 52.70M 38.98M

Annual Cash Flow Statements for MoonLake Immunotherapeutics

This table details how cash moves in and out of MoonLake Immunotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Change in Cash & Equivalents		 -271 412 31 -0.67
Net Cash From Operating Activities		 -117 -43 -56 -0.61
Net Cash From Continuing Operating Activities		 -117 -43 -56 -0.61
Net Income / (Loss) Continuing Operations		 -121 -44 -65 0.00
Consolidated Net Income / (Loss)		 -121 -44 -65 -
Depreciation Expense		 1.38 0.37 0.16 -
Non-Cash Adjustments To Reconcile Net Income		 5.63 7.08 9.87 -4.57
Changes in Operating Assets and Liabilities, net		 -2.35 -6.15 -1.43 3.96
Net Cash From Investing Activities		 -206 -25 -32 0.00
Net Cash From Continuing Investing Activities		 -206 -25 -32 0.00
Purchase of Property, Plant & Equipment		 -0.52 -0.28 -0.02 -
Purchase of Investments		 -350 -176 -42 0.00
Sale and/or Maturity of Investments		 145 151 9.90 -
Net Cash From Financing Activities		 51 480 120 -0.06
Net Cash From Continuing Financing Activities		 51 480 120 -0.06
Repayment of Debt		 0.00 0.00 -15 -0.06
Repurchase of Common Equity		 -0.00 0.00 0.00 0.00
Issuance of Common Equity		 53 482 0.00 0.00
Other Financing Activities, net		 -1.23 -2.75 135 -
Other Net Changes in Cash		 0.13 - 0.01 -
Cash Income Taxes Paid		 0.15 0.04 0.00 -

Quarterly Cash Flow Statements for MoonLake Immunotherapeutics

This table details how cash moves in and out of MoonLake Immunotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -195 33 -116 7.27 133 -184 452 11 -1.70 -52
Net Cash From Operating Activities		 -48 -25 -28 -15 -12 -9.25 -12 -9.02 -12 -9.35
Net Cash From Continuing Operating Activities		 -48 -25 -28 -15 -12 -9.25 -12 -9.02 -12 -9.35
Net Income / (Loss) Continuing Operations		 -46 -36 -25 -14 -7.89 -12 -12 -12 -16 -15
Consolidated Net Income / (Loss)		 -46 -36 -25 -14 -7.89 -12 -12 -12 -16 -15
Depreciation Expense		 1.30 0.03 0.03 0.02 0.36 0.00 0.00 0.00 0.16 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.91 2.52 2.16 1.85 1.54 1.47 1.41 2.66 2.59 2.64
Changes in Operating Assets and Liabilities, net		 -2.47 8.28 -5.32 -2.84 -6.35 0.89 -1.22 0.53 2.12 2.75
Net Cash From Investing Activities		 -147 58 -88 -29 117 -174 13 20 9.90 -42
Net Cash From Continuing Investing Activities		 -147 58 -88 -29 117 -174 13 20 9.90 -42
Purchase of Property, Plant & Equipment		 -0.18 -0.13 - -0.21 -0.28 - - 0.00 -0.00 -
Purchase of Investments		 -147 -29 -86 -88 - -176 - 0.00 0.00 -
Sale and/or Maturity of Investments		 -0.21 88 -1.30 59 117 1.36 13 20 9.90 -
Net Cash From Financing Activities		 0.15 0.18 - 51 28 - 451 0.00 0.00 -
Net Cash From Continuing Financing Activities		 0.15 0.18 - 51 28 - 451 0.00 0.00 -
Other Financing Activities, net		 0.15 0.18 - -1.56 -2.75 - - 0.00 - -
Other Net Changes in Cash		 0.42 -0.33 - - - 0.01 - - -0.01 0.07

Annual Balance Sheets for MoonLake Immunotherapeutics

This table presents MoonLake Immunotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 478 527 77 9.68 117
Total Current Assets		 474 514 77 9.64 1.62
Cash & Equivalents		 180 451 40 8.04 1.34
Short-Term Investments		 268 60 33 0.00 -
Accounts Receivable		 2.84 1.06 0.22 0.15 -
Prepaid Expenses		 23 2.10 4.18 1.45 0.28
Plant, Property, & Equipment, net		 0.72 0.32 0.05 0.05 0.00
Total Noncurrent Assets		 2.92 12 0.28 0.00 115
Other Noncurrent Operating Assets		 2.92 12 0.28 0.00 115
Total Liabilities & Shareholders' Equity		 478 527 77 9.68 117
Total Liabilities		 25 13 8.08 21 4.15
Total Current Liabilities		 22 9.97 7.67 21 0.13
Accounts Payable		 8.99 1.84 0.25 1.57 -
Accrued Expenses		 12 6.93 7.26 4.52 0.07
Other Current Liabilities		 1.37 1.20 0.15 0.00 -
Total Noncurrent Liabilities		 2.08 3.08 0.41 0.24 4.03
Noncurrent Employee Benefit Liabilities		 0.62 0.58 0.28 0.24 4.03
Other Noncurrent Operating Liabilities		 1.46 2.50 0.13 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 453 513 69 -12 -2.52
Total Preferred & Common Equity		 447 496 49 -12 -2.52
Total Common Equity		 447 496 49 -12 -2.52
Common Stock		 677 610 129 42 0.00
Retained Earnings		 -236 -117 -81 -54 -2.52
Accumulated Other Comprehensive Income / (Loss)		 5.00 2.36 0.35 -0.17 -
Noncontrolling Interest		 6.57 18 20 0.00 -

Quarterly Balance Sheets for MoonLake Immunotherapeutics

This table presents MoonLake Immunotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 518 545 564 500 507 67 89
Total Current Assets		 512 537 554 500 506 67 89
Cash & Equivalents		 376 343 458 318 502 50 41
Short-Term Investments		 118 177 89 178 0.00 13 42
Accounts Receivable		 2.41 1.68 1.50 0.72 0.62 0.38 0.60
Prepaid Expenses		 16 15 5.04 3.31 3.96 3.08 4.48
Plant, Property, & Equipment, net		 0.58 0.48 0.51 0.04 0.04 0.05 0.05
Total Noncurrent Assets		 5.32 7.51 10 0.17 0.21 0.25 0.00
Other Noncurrent Operating Assets		 5.32 7.51 10 0.17 0.21 0.25 -
Total Liabilities & Shareholders' Equity		 518 545 564 500 507 67 89
Total Liabilities		 23 15 12 11 7.51 7.68 6.02
Total Current Liabilities		 20 12 8.91 10 7.13 7.28 6.02
Accounts Payable		 11 5.14 3.48 3.40 4.36 3.83 1.06
Accrued Expenses		 7.93 5.82 4.12 6.75 2.62 3.30 4.96
Other Current Liabilities		 1.44 1.32 1.30 0.16 0.16 0.16 -
Total Noncurrent Liabilities		 2.63 2.56 2.82 0.27 0.38 0.41 0.00
Noncurrent Employee Benefit Liabilities		 0.69 0.54 0.46 0.26 0.32 0.31 0.00
Other Noncurrent Operating Liabilities		 1.94 2.02 2.36 0.01 0.05 0.09 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 496 530 552 490 499 59 83
Total Preferred & Common Equity		 488 521 543 425 490 42 55
Total Common Equity		 488 521 543 425 490 42 55
Common Stock		 675 672 670 531 590 131 124
Retained Earnings		 -190 -155 -130 -109 -100 -90 -69
Accumulated Other Comprehensive Income / (Loss)		 2.83 3.26 2.69 2.88 0.04 0.34 0.25
Noncontrolling Interest		 7.31 9.37 9.83 65 9.31 17 27

Annual Metrics And Ratios for MoonLake Immunotherapeutics

This table displays calculated financial ratios and metrics derived from MoonLake Immunotherapeutics' official financial filings.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -174.17% 32.18% -1,307.00% 0.00%
EBIT Growth		 -175.01% 31.77% -1,310.61% 0.00%
NOPAT Growth		 -164.38% 16.81% -1,323.56% 0.00%
Net Income Growth		 -175.06% 31.67% -1,320.01% 0.00%
EPS Growth		 -158.90% 57.06% -448.39% 0.00%
Operating Cash Flow Growth		 -172.54% 23.47% -9,046.87% 0.00%
Free Cash Flow Firm Growth		 -135.71% 6.74% 0.00% 0.00%
Invested Capital Growth		 116.04% 174.16% 28.52% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -45.18% 17.06% -362.89% 0.00%
EBIT Q/Q Growth		 -46.71% 16.38% -364.08% 0.00%
NOPAT Q/Q Growth		 -31.83% 2.99% -368.34% 0.00%
Net Income Q/Q Growth		 -46.54% 16.29% -376.74% 0.00%
EPS Q/Q Growth		 -8.00% -1.39% -218.06% 0.00%
Operating Cash Flow Q/Q Growth		 -44.90% -1.78% -225.23% 0.00%
Free Cash Flow Firm Q/Q Growth		 -22.83% -30.08% 0.00% 0.00%
Invested Capital Q/Q Growth		 240.14% 139.18% -275.64% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.23% 100.21% 100.06% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 99.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -25.08% -15.14% -225.85% -9.01%
Cash Return on Invested Capital (CROIC)		 -2,626.49% -1,760.81% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -24.45% -14.16% -147.01% 1.27%
Return on Equity Simple (ROE_SIMPLE)		 -27.13% -8.89% -131.92% 39.01%
Net Operating Profit after Tax (NOPAT)		 -100 -38 -46 -3.20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.40% -2.12% -58.21% 19.30%
Return On Investment Capital (ROIC_SIMPLE)		 -22.09% -7.38% -66.23% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -121 -44 -64 -4.57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -120 -44 -64 -4.57
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 7.74 7.61 11.32 0.00
Price to Tangible Book Value (P/TBV)		 7.74 7.61 11.32 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 562.85 1,320.26 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.00 -1.29
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -1.00 -1.14 -0.60
Leverage Ratio		 1.04 1.04 1.51 1.25
Compound Leverage Factor		 1.04 1.04 1.51 1.25
Debt to Total Capital		 0.00% 0.00% 0.00% 447.09%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 447.09%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 2.16%
Noncontrolling Interests to Total Capital		 1.45% 3.47% 28.89% 0.00%
Common Equity to Total Capital		 98.55% 96.53% 71.11% -349.25%
Debt to EBITDA		 0.00 0.00 0.00 -3.28
Net Debt to EBITDA		 0.00 0.00 0.00 -1.52
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -4.69
Net Debt to NOPAT		 0.00 0.00 0.00 -2.18
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 84.21 173.96 37.95 -6.61
Noncontrolling Interest Sharing Ratio		 2.52% 6.47% 34.91% 114.12%
Liquidity Ratios		 - - - -
Current Ratio		 21.11 51.59 9.98 0.46
Quick Ratio		 20.07 51.38 9.44 0.39
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 -103 -44 -47 0.00
Operating Cash Flow to CapEx		 -22,441.34% -15,029.18% -349,140.48% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 5.36 2.48 -3.35 -4.68
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.88 5.83 1.34 0.00
Enterprise Value (EV)		 3,019 3,278 501 153
Market Capitalization		 3,460 3,771 553 146
Book Value per Share		 $6.99 $7.94 $0.93 ($0.79)
Tangible Book Value per Share		 $6.99 $7.94 $0.93 ($0.79)
Total Capital		 453 513 69 3.35
Total Debt		 0.00 0.00 0.00 15
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -448 -511 -72 6.96
Capital Expenditures (CapEx)		 0.52 0.28 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.80 -6.81 -3.27 -4.49
Debt-free Net Working Capital (DFNWC)		 452 504 69 3.55
Net Working Capital (NWC)		 452 504 69 -11
Net Nonoperating Expense (NNE)		 21 6.19 19 1.34
Net Nonoperating Obligations (NNO)		 -448 -511 -72 6.96
Total Depreciation and Amortization (D&A)		 1.38 0.37 0.16 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 ($1.89) ($1.46) ($1.70) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 62.87M 98.25M 29.36M 14.81M
Adjusted Diluted Earnings per Share		 ($1.89) ($1.46) ($1.70) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 62.87M 98.25M 29.36M 14.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.31)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 64.01M 63.89M 52.70M 11.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -100 -38 -46 -3.20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MoonLake Immunotherapeutics

This table displays calculated financial ratios and metrics derived from MoonLake Immunotherapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -502.10% -210.60% -99.77% -13.75% 54.10% 21.33% 29.10% 23.10% -147.29% -134.33%
EBIT Growth		 -491.02% -210.79% -99.95% -13.90% 52.34% 21.33% 29.09% 23.09% -147.74% -134.30%
NOPAT Growth		 -229.90% -232.23% -131.90% -53.27% 9.99% 12.14% 25.30% 18.89% -133.90% -135.68%
Net Income Growth		 -488.23% -210.81% -100.42% -14.38% 52.10% 21.18% 29.07% 23.05% -147.72% -134.44%
EPS Growth		 -235.14% -211.11% 15.22% 4.35% -82.21% 33.33% -35.29% 85.49% -60.15% 89.73%
Operating Cash Flow Growth		 -292.68% -173.22% -129.38% -65.64% -6.45% 1.08% 41.43% 36.38% -142.77% -363.27%
Free Cash Flow Firm Growth		 -129.88% -946.91% -626.75% 71.63% -25.55% -103.65% -104.87% -146.21% 0.00% 0.00%
Invested Capital Growth		 116.04% 124.89% 482.21% 235.39% 174.16% -610.93% -246.16% 94.85% 28.52% -100.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -25.18% -45.99% -77.58% -77.08% 35.42% 6.10% -1.11% 25.82% -10.67% 15.37%
EBIT Q/Q Growth		 -28.68% -45.96% -77.49% -77.29% 32.33% 6.10% -1.11% 25.82% -11.70% 15.36%
NOPAT Q/Q Growth		 -15.00% -40.99% -54.28% -31.88% -15.81% 1.59% -1.97% 22.55% -13.04% 16.32%
Net Income Q/Q Growth		 -28.47% -45.87% -77.16% -77.19% 32.12% 5.94% -1.10% 25.80% -11.71% 15.36%
EPS Q/Q Growth		 10.71% -43.59% 11.36% -22.22% 305.56% 60.87% 0.00% -221.05% 870.37% 20.59%
Operating Cash Flow Q/Q Growth		 -91.79% 9.38% -86.58% -21.10% -33.44% 23.92% -34.73% 22.18% -24.00% 54.95%
Free Cash Flow Firm Q/Q Growth		 1.32% -11.01% -48.26% -41.54% -349.39% 22.94% 94.21% -526.51% -113.06% 2.80%
Invested Capital Q/Q Growth		 240.14% -84.59% 91.91% 114.74% 139.18% -136.70% 32.02% -17.62% -275.64% -148.66%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.09% 100.26% 100.32% 100.51% 100.56% 100.25% 100.08% 100.09% 100.07% 100.06%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -25.08% -16.80% -11.32% -14.99% -15.14% -18.41% -18.79% -145.72% -225.85% -14.04%
Cash Return on Invested Capital (CROIC)		 -2,626.49% -5,319.84% -662.55% -974.90% -1,760.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -24.45% -15.57% -11.11% -14.33% -14.16% -15.45% -17.51% -115.85% -147.01% -3.68%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -16.95% -11.19% -8.45% 0.00% -12.39% -11.39% -144.87% 0.00% -24.47%
Net Operating Profit after Tax (NOPAT)		 -35 -30 -21 -14 -11 -9.08 -9.23 -9.05 -12 -10
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.44% -1.20% -0.66% -0.03% 0.90% -0.88% -1.05% -3.86% -14.67% -10.42%
Return On Investment Capital (ROIC_SIMPLE)		 -7.65% - - - -2.05% - - - -17.00% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -46 -36 -25 -14 -7.84 -12 -12 -12 -16 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -36 -25 -14 -7.48 -12 -12 -12 -16 -15
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 7.74 6.60 5.39 5.91 7.61 8.38 5.49 26.84 11.32 7.40
Price to Tangible Book Value (P/TBV)		 7.74 6.60 5.39 5.91 7.61 8.38 5.49 26.84 11.32 7.40
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 562.85 1,733.99 224.58 501.12 1,320.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -1.00 -0.99 -1.00 -1.00 -1.01 -1.00 -1.96 -1.14 -0.44
Leverage Ratio		 1.04 1.03 1.02 1.03 1.04 1.03 1.02 3.57 1.51 1.06
Compound Leverage Factor		 1.04 1.03 1.02 1.03 1.04 1.03 1.02 3.57 1.51 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.45% 1.47% 1.77% 1.78% 3.47% 13.22% 1.87% 28.95% 28.89% 33.04%
Common Equity to Total Capital		 98.55% 98.53% 98.23% 98.22% 96.53% 86.78% 98.13% 71.04% 71.11% 66.96%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 84.72 85.49 114.11 164.89 174.19 202.72 215.53 86.60 40.01 40.22
Noncontrolling Interest Sharing Ratio		 2.52% 7.31% 1.82% 4.41% 6.47% 16.08% 6.80% 20.50% 34.91% 73.82%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 21.11 25.51 43.71 62.13 51.59 48.51 70.97 9.14 9.98 14.71
Quick Ratio		 20.07 24.72 42.46 61.56 51.38 48.19 70.42 8.71 9.44 13.97
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -38 -38 -34 -23 -16 -3.64 -4.72 -82 -13 100
Operating Cash Flow to CapEx		 -27,609.79% -19,120.35% 0.00% -7,058.95% -4,336.91% 0.00% 0.00% 0.00% -1,159,598,200.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 5.36 1.58 10 5.33 2.48 -6.34 -2.68 -3.94 -3.35 -0.89
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.88 7.91 13 9.27 5.83 -5.45 -4.51 73 1.34 -110
Enterprise Value (EV)		 3,019 2,734 2,298 2,672 3,278 3,128 2,195 1,081 501 353
Market Capitalization		 3,460 3,221 2,808 3,209 3,771 3,559 2,688 1,127 553 409
Book Value per Share		 $6.99 $7.64 $8.15 $8.49 $7.94 $6.80 $9.29 $0.80 $0.93 $1.05
Tangible Book Value per Share		 $6.99 $7.64 $8.15 $8.49 $7.94 $6.80 $9.29 $0.80 $0.93 $1.05
Total Capital		 453 496 530 552 513 490 499 59 69 83
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -448 -494 -520 -547 -511 -496 -502 -63 -72 -83
Capital Expenditures (CapEx)		 0.18 0.13 0.00 0.21 0.28 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.80 -1.69 4.80 -2.38 -6.81 -6.28 -2.55 -3.83 -3.27 -0.94
Debt-free Net Working Capital (DFNWC)		 452 492 525 545 504 490 499 59 69 83
Net Working Capital (NWC)		 452 492 525 545 504 490 499 59 69 83
Net Nonoperating Expense (NNE)		 12 5.94 3.35 0.10 -2.63 2.54 3.12 3.17 4.78 4.40
Net Nonoperating Obligations (NNO)		 -448 -494 -520 -547 -511 -496 -502 -63 -72 -83
Total Depreciation and Amortization (D&A)		 1.30 0.03 0.03 0.02 0.36 0.00 0.00 0.00 0.16 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.50) ($0.56) ($0.39) ($0.44) $0.37 ($0.18) ($0.23) ($0.23) $2.08 ($0.27)
Adjusted Weighted Average Basic Shares Outstanding		 62.87M 62.90M 62.87M 125.27M 49.12M 53.52M 43.72M 39.06M 29.36M 36.93M
Adjusted Diluted Earnings per Share		 ($0.50) ($0.56) ($0.39) ($0.44) $0.37 ($0.18) ($0.23) ($0.23) $2.08 ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 62.87M 62.90M 62.87M 125.27M 49.12M 53.52M 43.72M 39.06M 29.36M 36.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 64.01M 63.91M 63.88M 63.87M 63.89M 62.45M 62.45M 52.70M 52.70M 38.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -35 -30 -21 -14 -11 -9.08 -9.23 -9.05 -12 -10
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About MoonLake Immunotherapeutics' Financials

When does MoonLake Immunotherapeutics's financial year end?

According to the most recent income statement we have on file, MoonLake Immunotherapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has MoonLake Immunotherapeutics' net income changed over the last 3 years?

MoonLake Immunotherapeutics' net income appears to be on an upward trend, with a most recent value of -$121.24 million in 2024, rising from -$4.54 million in 2021. The previous period was -$44.08 million in 2023. See where experts think MoonLake Immunotherapeutics is headed by visiting MoonLake Immunotherapeutics' forecast page.

What is MoonLake Immunotherapeutics's operating income?
MoonLake Immunotherapeutics's total operating income in 2024 was -$143.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $143.09 million
How has MoonLake Immunotherapeutics revenue changed over the last 3 years?

Over the last 3 years, MoonLake Immunotherapeutics' total revenue changed from $0.00 in 2021 to $0.00 in 2024, a change of 0.0%.

How much debt does MoonLake Immunotherapeutics have?

MoonLake Immunotherapeutics' total liabilities were at $24.54 million at the end of 2024, a 88.1% increase from 2023, and a 491.4% increase since 2020.

How much cash does MoonLake Immunotherapeutics have?

In the past 4 years, MoonLake Immunotherapeutics' cash and equivalents has ranged from $1.34 million in 2020 to $451.17 million in 2023, and is currently $180.43 million as of their latest financial filing in 2024.

How has MoonLake Immunotherapeutics' book value per share changed over the last 3 years?

Over the last 3 years, MoonLake Immunotherapeutics' book value per share changed from -0.79 in 2021 to 6.99 in 2024, a change of -983.4%.


Related Companies

This page (NASDAQ:MLTX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored